Cybin

Last updated
Cybin IRL
Industry Pharmaceutical; Psychedelic medicine
Founded2019;6 years ago (2019)
Headquarters
Toronto
,
Canada
Website cybin.com

Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines. [1] [2] [3]

Contents

The company's drug candidates include psilocybin (CYB001), [4] CYB002 (discontinued), [5] CYB003 (deuterated psilocin), [6] [7] [8] [9] CYB004 (deuterated dimethyltryptamine (DMT)), [10] CYB005 (deuterated phenethylamine derivative), [11] [12] [13] and CYB006. [14] [15]

As of January 2025, CYB003 is in phase 3 clinical trials. [6] [7] The drug is one of the only other psychedelic besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development. [16] [17]

In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics. [18]

See also

References

  1. ↑ Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L (May 2021). "The Therapeutic Potential of Psilocybin". Molecules. 26 (10): 2948. doi: 10.3390/molecules26102948 . PMC   8156539 . PMID   34063505.
  2. ↑ Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. (1 September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry". Psychedelic Medicine. 1 (3): 150–165. doi:10.1089/psymed.2023.0013. ISSN   2831-4425. Cybin is currently launching a pilot study of a psilocybin analogue that may produce psychoactive effects for only 4 hours.
  3. ↑ Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (December 2023). "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders". Drug Discov Today. 28 (12): 103818. doi:10.1016/j.drudis.2023.103818. PMID   37925136.
  4. ↑ "Psilocybin - Cybin - AdisInsight". adisinsight.springer.com.
  5. ↑ "Delving into the Latest Updates on CYB-002 with Synapse". Synapse. 23 January 2025. Retrieved 31 January 2025.
  6. 1 2 "CYB 003 - AdisInsight". adisinsight.springer.com.
  7. 1 2 "Delving into the Latest Updates on CYB-003 with Synapse". synapse.patsnap.com.
  8. ↑ Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, Reichelt A, Hartsel J, Nivorozhkin A, Inamder A, Varty G (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P361. In Vitro and In Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 47 (Suppl 1): 220–370 (271). doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  9. ↑ Inamdar A, Morgan M, Krakowsky J, Reichelt A, Canal C, Mueller T, Avery K, Pathare P, Hartsel J, Nivorozhkin A, Varty G, Palfreyman M (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P362. Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 47 (Suppl 1): 220–370 (271–272). doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  10. ↑ "CYB 004 - AdisInsight". adisinsight.springer.com.
  11. ↑ "CYB 005 - AdisInsight". adisinsight.springer.com.
  12. ↑ "Delving into the Latest Updates on CYB-005 with Synapse". synapse.patsnap.com.
  13. ↑ "| BioWorld". www.bioworld.com.
  14. ↑ Psychedelic Alpha (29 June 2021). "Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement". Psychedelic Alpha. Retrieved 31 January 2025.
  15. ↑ "Development Pipeline". Cybin.
  16. ↑ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID   38831049.
  17. ↑ Michael Haichin (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  18. ↑ Cybin Inc. (14 December 2020). "CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings". GlobeNewswire News Room. Retrieved 6 February 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.